Chapter 6

Probiotics and Allergic Diseases — Usefulness of Animal Models — From Strains Selection to Mechanistic Studies

Elodie Neau, Marie-José Butel and Anne-Judith Waligora-Dupriet

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/59486

1. Introduction

The prevalence of allergies has dramatically and rapidly increased over the past decades in areas with a “westernized” or “industrialized” lifestyle. This increase and the dichotomy in the rate of allergic disease between industrialized and developing countries are two lines of evidence suggesting that environmental changes are a major factor in the development of allergies. There is mounting evidence that the microbiota is a key environmental factor that influences oral tolerance. Alterations in the sequential establishment of gut microbiota observed in western countries could therefore be responsible for a T-helper balance deviation toward a Th2 profile, a major factor in the rise of allergic diseases. Likewise treatment with broad spectrum antibiotics in infancy leading to microbiota alterations and dysbiosis, is associated with increased susceptibility to allergy [1]. Indeed recent epidemiological studies have linked factors influencing microbiota establishment and risk of allergy [2,3]. Hence, increasing evidences suggest that the composition of the microbiota influences intestinal barrier functions [4,5] and both local [6] and systemic immune responses [7]. A specific signature of the microbiota has been associated with allergy sensitivity [8-10]. This hypothesis has been confirmed by studies using mice models which have shown that the gut microbiota is likely to play a role in the development of oral tolerance. We and other have shown that the lack of gut microbiota in germ free mice is associated with the development of Th2 and IgE responses to dietary antigens [11,12]. The specific gut microbiota observed in mice with food allergy by Noval-Rivas et al was able of transmitting disease susceptibility to naive germ-free recipients [9]. In humans, several studies highlighted differences in the composition of bacterial communities in the feces of subject with or without allergic diseases; however, available epidemiological studies remain controversial [13]. Numerous studies support that a
low diversity of the gut microbiota in infancy is important, more than the prevalence of specific bacterial taxa but this low diversity can also be attributed to specific bacterial group, such as Bacteroidetes and Proteobacteria [14-17]. Interestingly, Ling et al described distinct alterations of the gut microbiota in IgE and non-IgE mediated food allergy [18]. Despite discrepancies between clinical studies, the likely relationship between the intestinal microbiota and allergy assess the usefulness of modulation of the gut microbiota that may help prevent and manage allergic diseases. This notion supports the use of probiotics, prebiotics and symbiotics.

If present results of clinical trials do not allow concluding unambiguously in favor of probiotics, studies have shown the benefits of this approach, justifying further research in this direction [13,19-21]. Recent reviews reported studies showing the beneficial effects in the prevention of atopic dermatitis [19-21]. Prevention of respiratory allergies also seems possible [21]. Differences between studies are most likely due to differences in the populations studied - in terms of type of allergy, evolutionary stage of the disease, environment, genetic background - but also to the various probiotic used in terms of strain, dose, duration and time of administration in relation to the development of allergy, and finally the follow-up period [13, 19]. The combined prenatal and postnatal administration of probiotics appears more effective [21]. However, the conflicting results reported today do not allow the recommendation of the use of probiotics in prevention of allergy by expert committees. Despite the promising results on prevention and treatment of allergic diseases by various strains, EFSA did not delivered favorable opinions on requests. Progress in our basic knowledge of probiotic strains, in strain selection, and in understanding their mechanisms of action is needed to give credibility to the health claims made for probiotics and especially for the design of efficacious therapeutic agents. For these reasons, animal models constitute unavoidable tools for biomedical research. They are used for their potential to mimic the human disease process, and allow better understanding of key events of allergic disease development.

2. Animal models of food allergy, asthma and atopic dermatitis

In this chapter, only animal models that have been used to characterize the impact of probiotics on allergy will be described.

The impact of probiotics on allergy – including food allergy, asthma and atopic dermatitis – was mainly studied on small laboratory animals (mice and rats), but domestic animals, as dogs and piglets, were also used. It is important to carefully choose animal model because it can deeply affect the study. Indeed, genetic predispositions condition IgE responsiveness [22].

2.1. Rodent models

2.1.1. Mice model

Mice are the first model organism because of its easy reproduction and its low cost of maintenance. This model does not completely mirror the human but it shares with him similar mechanisms of immune regulation, notably in T cell polarization [23]. These animals have the
capacity to produce IgE and IgG1 antibodies, and, depending on their genetic background, strains can be divided into high or low IgE responders [22]. There are also differences in their ability to produce Th1 and Th2 cytokines.

Murine models of food allergy and asthma have been investigated in several strains, including BALB/c, C57BL/6 and C3H/HeJ. BALB/c strain is the most commonly used in models of experimental induced allergy. Indeed, BALB/c mice develop a strong Th2 response following sensitization and challenge with an allergen, with higher levels of allergen-specific IgE. It can be explained by a genetic predisposition towards the development of Th2 cells, implicate in allergy process [24]. This bias is caused by the loss of functional IL-12 receptor which leads to promote the generation of IL-4-producing cells. Indeed, IL-12 favors the generation of Th1 effector cells which antagonize the effects of IL-4 [25]. Many authors have succeeded to sensitize BALB/c mice with different allergens, such as ovalbumin (OVA) [26,27], ovomucoid [27] and β-lactoglobulin [28]. However, according to protocols, teams have obtained conflicting results. For instance, Morafo et al have demonstrated that BALB/c mice failed to produce cow’s milk-specific IgE and did not reproduce symptoms after cow’s milk challenge [29].

C57BL/6 mice are intermediate IgE responders [22] and have been used successfully in allergen challenge studies [30-32]. C57BL/6 strain has the advantage of being stable and having its genome entirely sequenced. Moreover, the most available knock-out strains mice are created on C57BL/6 genetic background.

C3H/HeJ strain is also used [33-35]. It has a mutation in the gene tlr4 which recognize LPS. This loss of function leads to a higher susceptibility to allergy, with a skewing of the cytokine response to a Th2 phenotype and an aggravated anaphylactic reaction [36,37]. C3H/HeN strain, which don’t have this mutation, is also used to obtain an anaphylactic response [11].

One study has compared these three mice strains in a model of asthma [38]. After immunizations to OVA/alum, BALB/c strain develops an α-actin smooth muscle hyperplasia and an airway responsiveness which was more important than in C57BL/6 and C3H/HeJ. These results have been confirmed by Van Hove et al. [39]. The choice of the murine strain is therefore of great importance, and must be determined in accordance with objectives. Hence, in food allergy, BALB/c and C3H/HeJ strains are more relevant to study sensitization with a high IgE response and anaphylaxis, respectively [29].

Strain NC/Nga, firstly developed by Matsuda et al in 1997, is widely used in models of atopic dermatitis (AD) [40]. Inbred NC/Nga can develop skin lesion similar clinically (on face, neck, ears, nose and dorsal skin) and histologically (with an increase of the number of mast cells and CD4+T cells, and infiltration of numerous eosinophils) to human. IgE levels increase in association with clinical severity. These symptoms and signs appear when the mice are raised under conventional conditions, and not under specific pathogen-free conditions, environmental factors provoking AD-like signs [41]. BALB/c strain has also been used for this application [42].
2.1.2. Rat model

The rat is another small animal model to examine food allergy, but it is few implemented [43-45]. Due to the size of this species, it is possible to monitor within individual animals the kinetics of specific serum antibody responses. They have the capacity to produce IgE and IgG2a antibodies [46]. The Brown Norway strain is a suitable model with a high-IgE response after oral sensitization [47,48]. However, Dearman et al [49] have showed that the ability of this strain to mount IgE responses is somewhat variable and subject to a number of influences including environmental conditions and/or sub-clinical infection. Sprague-Dawley strain has also been used to test the impact of probiotic supplementation [44].

2.2. Large animal models

Swine and dogs are an example of large animal models that have been investigated for allergy. They are less commonly used because they are most expensive than rodents and their housing is uneasy. However, in many aspects, closer similarities exist between these large animal species and humans. First, dog’s gut anatomy and physiology and nutritional requirements are similar to humans [50]. Second, atopic dogs share many allergies with human. Indeed, it develops spontaneously allergic reaction to dust mites and foods for example, with an incidence of 10% [51]. In this way, dogs present frequently IgE-mediated food hypersensitivity, with clinical symptoms comparable to those of human including gastrointestinal and dermatologic reactions. Of this fact, this model can be utilized for mimicking and characterizing mechanisms involved in the development of food allergies in children. To the best of our knowledge, up to now, the impact of probiotics has been only study on atopic dermatitis [52,53].

Only two teams used swine model within the framework of food allergy [54] and asthma [55]. Swine presents a number of important advantages for study allergy. Indeed, they have a similarity with young children in terms of size, organ development, intestinal physiology, whether anatomically or histologically, mucosal immunity and disease progression [56]. They are able to produce IgG and IgE [51].

3. Protocols of allergic sensitization

Multiple methods are used to induce allergy in animal models. Differences between protocols consist of the nature and dose of the allergen, and the strategy used to sensitize the animal prior to challenge (route of exposure and use or not of an adjuvant). The number of sensitizations is also extremely variable from one study to another, between 1 and 4 per week, during 1 from 8 weeks, according to the model, the use or not of an adjuvant, and the route of exposure (Tables 1 to 3).

3.1. Allergens

Many allergens are used to sensitize the different animal species. Ovalbumin (OVA), the main protein found in egg white, is used in more than 50% of publications on probiotic and allergy.
Other major allergens are peanut extract in food allergy [30,35,43,57], birch pollen from *Betula verrucosa* (Bet v 1) [58-60] and house dust mite *Dermatophagoides pteronyssinus* (Der p) [32,61,62] in asthma. The capacity to induce the immune system to produce IgE antibodies, elicit allergic symptoms, and bind to allergen-specific IgE depend of allergen [63]. For example, by oral route, the allergenic potential of peanut extract is far higher than the one of cow’s milk [63], and egg, Brazil nut and spinach [64]. The different allergens induce different types of antibody isotype patterns, whether it be IgG1, IgG2a, IgE and IgA. The allergenic potential of these molecules depends on the size and physicochemical properties of the protein, the glycosylation status, the biologic and enzymatic activities and the way in which the protein is processed and presented to the immune system [64]. Moreover, all mice strains are not susceptible to the same allergens. For example, BALB/c genetic background is completely resistant to peanut-induced anaphylaxis unlike C3H strain [37]. Experimental and clinical data indicate a difference in gender susceptibility to allergic inflammation [65,66]. These differences appear to vary with the route of administration used (see 3.2).

The dose of allergen and its frequency of administration are also important parameters in the magnitude of the immune response. Kroghsbo et al. [27] have orally immunized BALB/c mice with a low (0.5 mg) or a high (5 mg) dose of OVA. Results revealed that the OVA dose had no impact on the production of IgG1 and IgA, but had an impact on production of IgG2a and IgE, with a higher level obtained with the higher dose of allergen. Nevertheless, the allergen dose administered should not be too high. Indeed, a high-dose of allergen can be associated with an induction of tolerance, while low-dose is known to induce sensitization [51,67]. In addition to the dose, the frequency of antigen exposure plays also a role. Nelde et al have showed that, after intraperitoneal (IP) sensitization of BALB/c mice, IgE synthesis was best induced by increasing the frequency of OVA application with low-dose than with few exposures with high doses [68]. The magnitude of the sensitization therefore depends on the type and the dose of the used allergen, but also on the route of administration (see below).

### 3.2. Route of exposure

The route by which antigen is administered has its advantages and disadvantages, and affects both the magnitude and the type of response obtained. It must be chosen depending on the purpose of the study. The route of delivery to animals should closely look like about the projected route of administration to humans. The most common routes for allergen administration are oral, IP and epicutaneous (EC) routes. Intra-nasal (IN) - for administration of pneumallergen in model of asthma [69], intra-tracheal (IT) [55], and subcutaneous routes (SC) [55,59,60,62,70,71] are more rarely employed.

#### 3.2.1. Oral route

To model food allergy, antigen administration via the gastrointestinal tract – in other words, by gavage (IG) – provides clear ties to the human condition, and it is thus very relevant for exposure to food antigens. Additionally, it has the advantage of being economical, convenient, and relatively safe. Oral route also allows testing different allergens to evaluate their allergenic potential [64]. Oral immunization does not discriminate between males versus females, with
no differences in their level of Th1 (i.e. IgG2a) or Th2-associated (i.e. IgE and IgG1) antibodies [65]. This route can be used for sensitization studies [30,33-35,43-45,72-75] but also for tolerance studies [76-78]. Consequently, this route is principally used to study the impact of probiotics on food allergy.

3.2.2. Intraperitoneal route

The intraperitoneal administration is a common technique in laboratory rodents. It can be used to administer large volumes of fluid safely, unlike oral route which only tolerate low volumes [79]. The pharmacokinetic of substances administered by this route is closed to those seen after oral administration, with a passage by the liver. Special care must be taken regarding the injected substances which should be sterile, isotonic and nonirritating. There are differences in sensitization according to the gender when this route is applied. Bonnegarde-Bernard et al have therefore showed that female mice C57BL/6 sensitized by intraperitoneal route develop higher level of allergen-specific IgE, IgG2a and IgA than males [65]. This route is used in experimental murine models of food allergy and asthma, in sensitization or tolerance induction studies [80-83].

3.2.3. Epicutaneous route

Some substances can also be administered directly to the skin surface (epicutaneous administration) for a topical affect. The allergen is captured by skin dendritic cells that migrate to the afferent lymph nodes and activate immune responses and allergen-specific cytokine production [84]. Several studies have demonstrated that this route allows to sensitize to various antigens, in the absence of adjuvant [85], with a strong Th2 response [86,87]. For that, they utilized occlusive dressings and/or prolonged exposure to the antigen. The extent of absorption of substances through the skin and into the systemic circulation depends on many parameters, as for example the surface area of application, the integrity of the skin and the contact time [79]. Contrary to the oral route, the epicutaneous administration is inadequate to discriminate the allergenic potential of proteins [64]. This route is very employed in atopic dermatitis model [52,53,66,88-95].

3.2.4. Comparison of routes of exposure

Several publications have compared the impact of these different routes of administration on sensitization. Animals can be sensitized to many allergens, but in an adjuvant-dependent manner, whatever the route practiced (IP, SC, IG, EC, and IN), with a significant production of allergen-specific IgE, IgG1 and IgG2a [49,64,85]. The maximal level of these immunologic markers is attained via the cutaneous route [85]. A mucosal administration (i.e. IG, SC or IN administrations) was shown to develop a robust allergen-specific IgA response by contrast with a cutaneous exposure [85]. The intraperitoneal route allowed a stronger IgE and IgG response compared with that obtained by oral route [49], but this response was weaker than the one observed with intranasal and epicutaneous allergen application [68]. Contrary to the oral route, intraperitoneal and epicutaneous administrations did not allow the induction of oral tolerance [87].
3.3. The use of adjuvant

Most proteins are poorly immunogenic or non-immunogenic when administered on their own. To increase the immune response and thus sensitize animals, the majority of experimental studies utilize an adjuvant. The latter leads to a Th2 skewing, and abrogates the establishment of oral tolerance [96, 97]. There are exogenous Th2 adjuvants as glycans, endogenous adjuvants as thymic stromal lymphopoietin (TSLP) and experimental adjuvants as cholera toxin, aluminum hydroxide and enterotoxin B from *Staphylococcus aureus*.

3.3.1. Cholera toxin

Cholera toxin (CT) is secreted by the bacterium *Vibrio cholerae*, which is responsible for aqueous diarrhea. The major effect of CT is to promote the uptake of antigen by antigen-presenting cells and to facilitate the presentation of antigen to T cells by favoring the intestinal permeability. Indeed, it induces *in vivo* the maturation and the migration of gastrointestinal dendritic cells (DCs) from the lamina propria to the mesenteric lymph nodes where they present antigen to naive T cells. CT also enhances the migration from the subepithelial dome region of Peyer’s patches to the interfollicular T-cell areas. This maturation of DCs also includes the up-regulation of the co-stimulatory molecules OX40L and TIM-4, known to facilitate differentiation of responder T cells into Th2 cells. The neutralization of these two molecules has been shown to abrogate Th2 skewing in the gastrointestinal tract [96, 98].

3.3.2. Aluminum hydroxide

Aluminum hydroxide (alum) rarely induces cellular immune responses. However, it slows down the rate of release of the antigen and in this way increases the duration of antigen interaction with the immune system. It also promotes macrophage uptake. Therefore, it enhances the immune response against the antigen [97,99].

3.3.3. Enterotoxin B from *Staphylococcus aureus*

The enterotoxin B (SEB) is produced by *Staphylococcus aureus* in a variety of environments, including food substrates [97]. It causes severe diarrhea, nausea and intestinal cramping often starting within a few hours of ingestion. In the same way as the cholera toxin, the SEB induces the up-regulation of co-stimulatory molecules TIM-4, but also CD80 and CD86, which promotes the Th2 skewing.

3.3.4. Impact of dose of adjuvant

Few studies have focused on the impact of dose adjuvant on sensitization. Kroghsbo *et al* have tested three different CT doses (0.1, 1 or 10 µg) on BALB/c mice, sensitized to ovomucoid or ovalbumin [27]. They have observed a clear dose-dependent response on antibody induction, with the strongest response at the highest CT dose for any of the tested antibody isotypes (IgG1, IgG2a, IgE, and IgA). They were able to determine a threshold value (between 0.1 and 1 µg) for the lowest CT dose needed for sensitization. A weak dose of CT (0.1 µg) leads to initiation of IgG1 production. To observe an IgE production, a higher dose of CT (10 µg) is necessary.
4. Probiotic administration

Animal models can be used to select probiotic strains which can prevent or manage allergy, and to study their mechanism of action. Indeed, these animal models can be discriminant. For instance, if number of studies showed a positive impact of probiotic supplementation in their models of allergy (Tables 4 to 6), Meijerink et al showed a strain specific effect in a peanut allergy model [57]. Lee et al studied the protective impact on OVA sensitization of four strains of Lactobacillus [100]. None of them induced a change in IgE levels. Moreover, one of them led to an increase in allergic response. Likewise, de Jonge et al have found similar levels of IgG1 and IgG2a in Brown Norway rats sensitized to peanut extract, receiving or not a strain of L. casei Shirota by gavage [43]. A lack of benefit of supplementation was also observed in three models of asthma [62,70,71,101]. Sometimes, an improvement of symptoms, with a decrease of clinical signs after oral challenge, but without correlation with a decrease in markers of sensitization can be also observed [54,58,59].

4.1. Evaluation of beneficial effect of probiotic

The beneficial effect of probiotic supplementation is evaluated according to the model used.

4.1.1. Models of anaphylaxis

In models of anaphylaxis, clinical markers are analyzed after challenge by allergen, according to a scale score based on observed clinical symptoms (number of itches, mobility during the experiment, swelling of eyes and/or noise, aspect of hair, and body temperature). Thang et al and Schouten et al have scored symptoms of systemic anaphylaxis as follows: 0=no symptoms; 1=pilar erecti, scratching and rubbing around the nose and head; 2=pilar erecti, reduced activity; 3=activity after prodding and lowered body temperature; 4=no activity after prodding, labored respiration, and lowered body temperature; 5=death [28,74]. There are other models of anaphylaxis, in particular murine models of intestinal anaphylaxis induced by OVA. Food allergy symptoms are then scored by the criteria of diarrhea and rectal temperature [102,103]. However, this model has not been used yet to evaluate the impact of probiotic.

4.1.2. Models of asthma

In models of asthma, there is no scale of scores. The impact of probiotic is estimated by the determination of the cellular composition of bronchoalveolar fluid (total cell count and proportion of each cell type – lymphocytes, neutrophils, eosinophils and monocytes), the evaluation of number of infiltrated inflammatory cells in lung, and by the measurement of bronchial hyperresponsiveness [70,81,104].

4.1.3. Models of atopic dermatitis

As in models of food allergy, a scale of scores can be used in models of atopic dermatitis. Matsuda et al have estimated clinical skin condition after sensitizations as follows: 0=none, 1=mild, 2=moderate, 3=severe, for each of these symptoms: itch, erythema/hemorrhage,
edema, excoriation/erosion and scaling/dryness [105]. The frequency and the duration of scratching, the numbers of infiltrated cells and the epidermal/auricular thickening can be also measured [88,90,105].

The limit of all these evaluations lies in its subjectivity despite a blind evaluation system. This subjectivity results in a problem of reproducibility of the method. An analysis of biological markers of allergic reaction, i.e. the dosage in plasma of mast cell protease-1 (MCP-1) and/or histamine release during mast cell degranulation, provides less subjective data than clinical score [30,34,35]. These models also allow evaluating sensitization through dosage of allergen-specific and total IgE, IgG1 and IgG2a [60,92,100].

4.2. Route and dose of probiotic supplementation

The dose of probiotic is often comprised between $10^6$ and $10^9$ CFU. When the dose of probiotic is tested, the highest dose shows, most of the time, better results [35,62,89,94,106]. Jan et al have tested three increasing doses of Lactobacillus gasseri (1, 2 and $4 \times 10^6$ CFU) in BALB/c mice, in a model of asthma. Only the highest dose ($4 \times 10^6$ CFU) caused a significant decrease in the number of monocytes, lymphocytes and neutrophils in bronchoalveolar lavage fluid [62].

In oral administration, we distinguish the intra-gastric (IG) administration, in other words the gavage (with a needle), from oral administration (PO) (probiotic mixed in water or food). These two routes of exposure are principally used for the probiotic supplementation and whatever the types of allergy study. Gavage allows giving a precise dose of bacteria, but it is constraining because each animal must be handled individually leading to an additional stress in animals. Administration of the probiotic strains in drinking water or food avoids these problems of stress, but it raises the problem of their stability. Moreover, it does not allow knowing precisely the amount of bacteria received per day per animal. Probiotic can also be given by intranasal administration in models of asthma, or by epicutaneous exposure in models of atopic dermatitis. Intranasal administration allows a contact more extended with the probiotic, and therefore a longer action. However, according to the protocols, an anesthesia is necessary [107,108]. It could affect the lung antigen deposition by changing the breathing pattern and airway reflexes in animal [109]. Pellaton et al have demonstrated that intranasal exposure is more effective than gavage, with a lesser infiltration of eosinophils, in a model of asthma [106].

4.3. Window and frequency of probiotic administration

In the window of administration, we will consider the number of weeks of supplementation as well as the number of administration per week. According to studies, the probiotic is administered between 1 to 15 weeks, during 3 to 7 days per week.

The term “prevention” refers to an administration of the probiotic that starts prior to sensitizations and continues throughout the experiment. On the contrary, the term “management/treatment” refers to an administration of the probiotic that starts after sensitizations until the end of protocol.

In studies, probiotic is mainly tested for prevention and therefore administrated until two weeks before the start of sensitizations. Meijerink et al began administration of probiotic by
gavage 14 days prior to sensitizations [57]. Each of the three strains of *Lactobacillus* had a different impact on allergy. The strain of *L. plantarum* WCFS1 have promoted allergic response (increase of IgE, IgG1 and MCP-1), the strain of *L. casei* Shirota had no impact on allergy, while the strain of *L. salivarius* HMI001 allowed the decrease of peanut-specific IgE and MCP-1. Yu *et al*, in a model of asthma, have given a strain of *L. rhamnosus* Lcr35 in BALB/c mice, 7 days before sensitizations. They observed a decrease in both bronchial hyperresponsiveness and number of cells in bronchoalveolar fluid [110]. Some studies have administered the probiotic in treatment, i.e. after the last sensitization, in models of food allergy and asthma, with a positive impact of supplementation. Schiavi *et al* have demonstrated, in a model of shrimp tropomyosin allergy, that the administration of VSL#3 during 20 days after the fourth sensitization allowed a decrease of clinical scoring and specific IgE, together with an induction of IgA on C3H/HeJ mice [34]. Similar results have been found in studies of Zhang *et al* [35], and Forsythe *et al* [111], with the administration of ImmuBalance™ in a model of food allergy, and with the gavage of strain *L. reuteri* ATCC 23272 in a model of asthma, respectively.

This high heterogeneity in the different protocols of probiotic administration make difficult, even impossible, comparisons between studies, and prevents establishment of an optimal administration scheme of probiotic. Comparison between prevention and management protocols shows that the window of administration plays a key role in the efficiency of probiotic, with a better effect in prevention. Indeed, in a model of food allergy, Kim *et al* [33] have showed, on C3H/HeJ mice sensitized to OVA, an improvement of allergic symptoms on the tail associated with a decrease of specific IgE in prevention, more important than those observed in treatment. Tanaka *et al* [42] in a model of atopic dermatitis and Yu *et al* [110] in a model of asthma have obtained comparable results. On the contrary, Bickert *et al* revealed a positive impact of probiotic, with an IP administration of *Escherichia coli* Nissle 1917 mixed with OVA, at the same time of sensitizations [31]. In study of Huang *et al*, similar effects of probiotics in prevention and treatment have been observed, suggesting that a long-term supplementation was not necessary [45]. Zuercher *et al* have obtained more contrasted results. They have observed that an oral administration of *Lactococcus lactis* NCC 2287 was effective in the management of food allergy symptoms in sensitized BALB/c mice, with a decrease in symptoms upon OVA challenge. However, this administration had no effect on the prevention of sensitization, with similar levels of OVA-specific IgE and IgG1, and MCP-1 [75].

### 4.4. Age and sanitary status of animals

The age and the sanitary status of animals have also an influence. In study of Lyons *et al*, the strain of *Bifidobacterium* AH1205 led to an increase of the percentage of CD4/CD25-cells in spleen and Peyer’s patches in pups but not in adult mice. The strain of *Bifidobacterium* AH1206 had the same impact, but in both pups and adult mice. These two strains were then tested in models of asthma and food allergy. Only the strain AH1206, which had an impact on pups and adult mice, showed a positive impact on allergy, with a decrease in bronchoalveolar cell number and OVA-specific IgE [112]. Similarly, depending on whether mice are germ-free or conventional, the induction of CD4/CD25/Foxp3-cells in spleen was not the same, with a lower induction in germ free, whatever the strain studied [112].
5. Concluding remarks

At a time when probiotics seem promising products for the prevention and treatment of allergy, fundamental and clinical studies failed the issuance of health claims and the implementation of recommendations by expert committees. The use of animal models is an essential step in the selection of strains of interest. However, such a use must be part of a rationalization process taking into account the 3Rs (Reduce, Reuse and Recycle) and ethical rules. *In vitro* models can bring the prior information on the behavior of the strains with respect to immunostimulatory capacities. For instance, Foligne *et al* have discriminated pro- and anti-inflammatory strains in a model of human peripheral blood mononuclear cells according to their cytokine profile [113]. Dendritic cells model can also allow selecting probiotic strains able to prime monocyte-derived DCs to drive the development of Treg cells [114]. Based on this first strain selection, animal models allow analyzing their mechanism of action. Indeed, probiotics can act on various actors of immunity. They can improve the barrier integrity [115], induce IgA secretion [28], and/or modulate T-helper balance, switching from Th2 to Th1 response [116] or enhancing Treg activity [34]. However, one should consider carefully the choice of the model and the design of probiotic administration to provide results which could be considered predictive for benefits in human and support the design of clinical studies.

| Strain     | Age  | Allergen | Route | Adjuvant | Window          | References |
|------------|------|----------|-------|----------|-----------------|------------|
| BALB/c     | 6 wks| BLG      | IP    | alum     | 1/wk, x1 wk     | [80]       |
| BALB/c male| 3 wks| BLG      | IP    | alum     | 1/wk, x3 wks    | [28]       |
| BALB/c female| 6 wks| OVA      | IP    | alum     | 1/2wks, x2      | [100]      |
| OVA-TCR female| 8 wks| OVA      | IG    | /        | 4/wk, x2 wks    | [73]       |
| C3H/HeOuJ female| 6 wks| peanut extract | IG | CT | 3/wk then 1/wk, x3 wks | [57] |
| BALB/c     | 6 wks| OVA      | IG    | CT       | 4/wk then 1/wk  | [75]       |
| Swiss Albino| 6-8 wks| OVA    | IP    | alum     | 1/wk, x2 wks    | [116]      |
| C3H/HeJ female| 8 wks| shrimp tropomyosin| IG | CT | 1/wk, x4 wks    | [34]       |
| BALB/c female| 18-22g| OVA    | IP    | SEB      | 3/wk, x1 wk     | [115]      |
| C3H/HeJ female| 5 wks| peanut extract | IG | CT | 1/wk, x8 wks    | [35]       |
| BALB/c male| 7 wks| OVA      | IP    | alum     | 1/wk, x2 wks    | [83]       |
| C3H/HeJ      | 5 wks| OVA      | IG    | CT       | 3/wk then 1/2wks, x2 | [72]       |
| Strain                      | Age     | Allergen   | Route | Adjuvant | Window          | References |
|-----------------------------|---------|------------|-------|----------|-----------------|------------|
| female                      |         |            |       |          |                 |            |
| C3H/HeOuJ female            | 3 wks   | whey protein | IG    | CT       | 1/wk, x6 wks    | [74]       |
| BALB/c                      | 8 wks   | OVA        | IP    | CT       | 1/wk, x3 wks    | [112]      |
| C57BL/6 female              | 8 wks   | peanut extract | IG    | CT       | 1/wk, x4 wks    | [30]       |
| C3H/HeJ female              | 3 wks   | OVA        | IG    | CT       | 3/wk then 1/2wks, x2 | [33]       |
| Sprague-Dawley male         | 150-180g| OVA        | IG and IP | Freund | 4/wk then 1/wk  | [44]       |
| Brown-Norway female         | 3 wks   | OVA        | IG    | /        | 7/wk, x6 wks    | [45]       |
| Brown-Norway female         | 3-4 wks | peanut extract | IG    | /        | 7/wk, x6 wks    | [43]       |
| Yorkshire                   | birth   | ovomucoid  | IP    | CT       | 1/wk, x3 wks    | [54]       |

**Table 1.** Protocols of sensitizations in food allergy

| Strain                      | Age     | Allergen   | Route | Adjuvant | Window          | References |
|-----------------------------|---------|------------|-------|----------|-----------------|------------|
| GF BALB/c female            | 8 wks   | Bet v 1    | SC    | alum     | 1/2wks, x3      | [60]       |
| BALB/c female               | 5 wks   | cedar pollen | SC    | /        | 5/2wks          | [70]       |
| GF BALB/c/c                 | birth   | Bet v 1    | SC    | alum     | 1/2wks, x3      | [59]       |
| BALB/c female               | 6 wks   | OVA        | IP    | alum     | 1/wk, x2 wks    | [91]       |
| BALB/c male                 | 20-25g  | OVA        | IP    | alum     | 1/wk, x2 wks    | [104]      |
| BALB/c female               | 6-8 wks | Der p      | SC    | Freund   | 1/wk, x2 wks    | [62]       |
| BALB/c female               | 6-10 wks| Bet v 1 + *P. pretense* 1 and 5 | IP    | alum     | 1/2wks, x3      | [58]       |
| BALB/c male                 | 5 wks   | OVA        | IP and IN | alum     | 1/2wks (IP) then 3/wk, x4 wks (IN) | [69]       |
| BALB/c female               | 3 wks   | cedar pollen | SC    | /        | 4/wk then 1/wk  | [71]       |
| BALB/c female               | 6-8 wks | OVA        | IP    | alum     | 1/2wks, x4      | [82]       |
| BALB/c male                 | 5-8 wks | OVA        | IP    | alum     | 1/wk, x2 wks    | [81]       |
| C57BL/6 female              | 6-8 wks | OVA        | IP    | alum     | 1/2wks, x2      | [31]       |
| BALB/c                      | 20-25g  | OVA        | IP    | alum     | 2/wk, x1 wk     | [111,117]  |
### Table 2. Protocols of sensitizations in asthma

| Strain                  | Age       | Allergen | Route | Adjuvant | Window       | References |
|-------------------------|-----------|----------|-------|----------|--------------|------------|
| C57BL/6 female          | 3-4 wks   | Der p2   | EC    | /        | 1/2wks, x3   | [32]       |
| BALB/c                  | 20-25g    | OVA      | IP    | CT       | 2/wk, x1 wk  | [112]      |
| BALB/c                  | -         | Der p1   | IP    | alum     | 1/wk, x3 wks | [61]       |
| BALB/c female           | 6 wks     | OVA      | IP    | alum     | 1/wk, x2 wks | [110]      |
| BALB/c female           | 4 wks     | OVA      | IP    | alum     | 1/2wks, x2   | [106]      |
| BALB/c female           | 8 wks     | OVA      | IP    | /        | 3/wk, x2 wks | [118]      |
| BALB/c female           | 6-8 wks   | OVA      | IP    | alum     | 1/2wks, x2   | [119]      |
| BALB/c female           | 8 wks     | Par j 1  | IP    | alum     | 1/3wks, x2   | [101]      |
| Duroc x Landrace        | 3 wks     | *Ascaris suum* | SC et IT | alum     | 1/2wks, x3 (SC) then 1/2wks, x2 (IT) | [55] |

### Table 3. Protocols of sensitizations in atopic dermatitis

| Strain                  | Age       | Allergen | Route | Adjuvant | Window       | References |
|-------------------------|-----------|----------|-------|----------|--------------|------------|
| NC/Nga                  | -         | FITC     | EC    | dibutyl phtalate | 1/wk, x3 wks | [92]       |
| NC/Nga male             | 6 wks     | DNCB     | EC    | /        | 2/wk, x2 wks | [120]      |
| NC/NgaTnd               | 8 wks     | /        | /     | /        | /            | [105]      |
| SKH-1/fr female         | 4 wks     | OVA      | EC    | /        | 1/3wks, x3   | [90]       |
| NC/Nga                  | 6 wks     | Df       | EC    | SDS      | 1/wk, x5 wks | [95]       |
| NC/NgaTndCrlj female    | 10 wks    | Df       | EC    | SDS      | 2/wk, x4 wks | [88]       |
| BALB/c female           | 8-10 wks  | OVA      | IP and EC | alum     | 1/2wks, x2 then 7/2wk, x3 | [94]       |
| NC/NgaTnd               | 5 wks     | /        | /     | /        | /            | [42]       |
| NC/Nga male             | 4 wks     | DF       | IP    | /        | 1/wk, x14 wks | [121]      |
| NC/Nga female           | 6 wks     | DNCB     | EC    | /        | 2/wk, x3 wks | [89]       |
| NC/Nga female           | birth     | /        | /     | /        | /            | [122]      |
| NC/Nga                  | 6 wks     | Df       | EC    | /        | 3/wk, x5 wks | [66]       |
| NC/Nga male             | 6 wks     | PCI      | EC    | /        | 1x            | [93]       |
| Beagle                  | birth     | Df       | EC    | /        | 3/wk, x1 wk  | [53]       |
| Beagle                  | birth     | Df       | EC    | /        | 2/wk, x12 wks | [52]       |
| Probiotic                      | Route | Window   | Dose            | Impact            | References |
|-------------------------------|-------|----------|-----------------|-------------------|------------|
| L. plantarum NRIC0380        | IG    | 3/wk, x4 wks | 200µg or 2mg   | sensitization     | [80]       |
| VSL#3                        | IG    | 7/wk, x5 wks | 15.10⁸ CFU     | clinic sensitization | [28]       |
| L. casei YIT9029 (L1)        | IG    | 7/wk, x3 wks | 2mg            | sensitization     | L1, L3, L4, ↗ L2 | [100]     |
| L. casei HY7201 (L2)         | IG    | 4/wk, x2 wks | 2mg            | clinic sensitization | ↘ LB, LC, BL | [73]       |
| L. brevis HY7401 (L3)        | IG    | 3/wk, x6 wks | 10⁹ CFU        | sensitization     | ↘ LP, ↘ LS, LC | [57]       |
| L. brevis HY7401 (LB)        | IG    | 3/wk, x3 wks | 7,5.10⁸ CFU    | clinic sensitization | P, ↘ M, M | [75]       |
| L. lactis WCFS1 (LP)         | PO    | 7/wk, x1,2 or 3 wk(s) | 5.10⁹ CFU/mL  | clinic sensitization | P, ↘ M, M | [75]       |
| Dahi                         | PO    | 7/wk, x3 wks | 7,5.10⁸ CFU    | clinic sensitization | ↘            | [34]       |
| Bifidobacterium              | IG    | 7/wk, x1 wk | 10⁹ CFU/mL     | clinic sensitization | ↘            | [115]      |
| ImmuBalance®                 | PO    | 7/wk, x4 wks | 0,5 or 1%      | clinic sensitization | ↘            | [35]       |
| L. pentosus 5-PT84           | PO    | 7/wk, x5 wks | 0,075%         | sensitization     | ↘            | [83]       |
| B. bifidum BGN4              | PO    | 7/wk, x7 wks (P) or 7/wk, x2 wks (M) | 0,2%           | clinic sensitization | ↘ P, M, P > M | [72]       |
| Immunofortis (IF)            | PO    | 7/wk, x10 wks | 2%             | clinic sensitization | ↘ IF, BB, SY, SY, IF, BB | [74]       |
| B. breve AH1205 (BB) symbiotic (SY) | PO    | 7/wk, x5 wks | 2.10⁹ CFU      | sensitization     | ↘ BL, BB, LS | [112]      |
| B. longum AH1206 (BL)        | IG    | 7/wk, x5 wks | 2.10⁹ CFU      | sensitization     | ↘ BL, BB, LS | [112]      |
| L. salivarius AH102 (LS)     | IG    | 7/wk, x3 wks | 7,5.10⁸ CFU    | clinic sensitization | ↘            | [30]       |
| LGG                          | IG    | 7/wk, x4 wks | 10⁹ CFU        | -                 | [44]       |
| B. animalis MB5              | IG    | 7/wk, x4 wks | 10⁹ CFU        | -                 | [44]       |
| Probiotic | Route | Window | Dose | Impact | References |
|-----------|-------|--------|------|--------|------------|
| LGG + *B. longum* BB536 | IG | 7/wk, x2, 3 or 10 wks | 0,5.10^9 CFU | sensitization | [45] |
| *L. casei* Shirota | IG | 7/wk, x8 wks | 10^9 CFU | sensitization | [43] |
| *L. lactis* MG1363 | IG | 7/wk, then 3/wk then 1/wk, x3 wks | 10^9 CFU | clinic sensitization | [54] |

Table 4. Protocols of probiotic administration in models of food allergy

| Probiotic | Route | Window | Dose | Impact | References |
|-----------|-------|--------|------|--------|------------|
| *B. longum* ssp. longum CCM7952 | IG | 1x (parents before coupling) | 2.10^8 CFU | sensitization | [60] |
| *E. faecalis* FK-23 | IG | 7/wk, x3 wks | 60mg | infiltration | [70] |
| *L. paracasei* NCC2461 | PO | 7/wk, x4 wks | 2.10^9 CFU/mL | clinic sensitization | [59] |
| *L. rhamnosus* Lcr35 | IG | 7/wk, x3 wks | 10^9 CFU/600µL | infiltration | [91] |
| *E. faecalis* FK-23 | IG | 7/wk, x4 wks | 60mg | infiltration | [104] |
| *L. gasseri* A5 | IG | 7/wk, x4 wks | 1,2 or 4.10^9 CFU | sensitization | [62] |
| *L. paracasei* NCC2461 *B. longum* NCC3001 | IN | day of sensitization (M) or 3/wk, x2 wks (P) | 5.10^9 CFU | sensitization | [58] |
| *L. crispatus* KT-11 (LC) LGG (LG) | PO | 7/wk, x8 wks | 5.10^7 CFU/g | clinic sensitization | [69] |
| *E. faecalis* FK-23 | IG | 7/wk, x3 wks | 30mg | sensitization | [71] |
| *L. salivarius* PM-A0006 | IG | 7/wk, x8 wks | 2.6 or 5.5.10^9 CFU, or 3.6.10^9 CFU | infiltration | [82] |
| *B. breve* M16V | IG | 7/wk, x2 wks | 10^8 CFU | infiltration | [81] |
| *E. coli* Nissle 1917 | IG | day of sensitization (M) or 7/wk, x4 wks (P) | 10^8 CFU | infiltration | [31] |
| *L. reuteri* ATCC23272 | IG | 7/wk, x1 wk | 10^8 CFU | infiltration | [111,117] |
| *L. casei* Shirota | IG | 3/wk, x4 wks | 10^8 CFU | sensitization | [32] |
| *B. breve* AH1205 (BB) *B. longum* AH1206 (BL) | IG | 7/wk, x2 wks | 2.10^9 CFU | infiltration | [112] |
| Probiotic                      | Route | Window                | Dose       | Impact                        | References |
|--------------------------------|-------|-----------------------|------------|-------------------------------|------------|
| L. salivarius AH102 (LS)       | IN    | 3/wk, x2 wks          | 10⁹ CFU   | sensitization                 | [61]       |
| E. coli Nissle 1917            | IN    | 7/wk, x3 wks (P) or 1 wk (M) | 10⁹ CFU   | infiltration sensitization    | \          |
|                                |       |                       |            |                               | \ P, M     |
|                                |       |                       |            |                               | \ P, M     |
| L. rhamnosus Lcr35             | IG    | 7/wk, x1 wk           | 10⁹ CFU   | infiltration                  | \ A, B     |
|                                |       |                       |            |                               | IN > IG    |
| L. paracasei NCC2461 (A)       | IN or IG | 7/wk, x1 wk          | 10⁹ CFU   | infiltration                  | \ LG, BB   |
| L. plantarum NCC1107 (B)       | IG    | 4/wk, x8 wks          | 10⁹ CFU   | infiltration                  | \ LG, BB   |
|                                |       |                       |            |                               | \         |
| LGG (LG)                       | IG    | 7/wk, x7 wks          | 10.10¹⁰ CFU | clinic                        | \         |
|                                |       |                       |            |                               | [118]      |
| L. rhamnosus HN001             | PO    | 7/wk, x7 wks          | 10.10¹⁰ CFU | clinic                        | \         |
|                                |       |                       |            |                               | [55]       |

Table 5. Protocols of probiotic administration in models of asthma

| Probiotic                      | Route | Window                | Dose       | Impact                        | References |
|--------------------------------|-------|-----------------------|------------|-------------------------------|------------|
| Vitreoscilla filiformis        | CUT   | 1/wk, x4 wks          | 20% v/v    | clinic sensitization          | \          |
|                                |       |                       |            |                               | [92]       |
| L. sakei probio 65             | IG    | 7/wk, x2 wks          | 5.10⁹ CFU/mL | clinic sensitization         | \          |
|                                |       |                       |            |                               | [120]      |
| ImmuBalance™                   | PO    | 7/wk, x2 wks          | 1,8.10⁹/g | clinic sensitization          | \          |
|                                |       |                       |            |                               | [105]      |
| L. rhamnosus Lcr35             | IG    | 7/wk, x8 wks          | 10⁹ CFU/600µL | clinic sensitization       | \          |
|                                |       |                       |            |                               | \         |
|                                |       |                       |            |                               | [90]       |
| L. plantarum CJLP55 (A)        | PO    | 7/wk, x8 wks          | 10⁶ CFU    | clinic sensitization          | \ A, B, C  |
| L. plantarum CJLP133 (B)       | PO    | 7/wk, x8 wks          | 10⁶ CFU    | clinic sensitization          | \ A, B, C  |
| L. plantarum CJLP136 (C)       | PO    | 7/wk, x8 wks          | 10⁶ CFU    | clinic sensitization          | \ A, B, C  |
|                                |       |                       |            |                               | [95]       |
| B. subtilis JCM20036           | IG    | 6/wk, x4 wks          | 1,2.10⁷ CFU | clinic sensitization          | \          |
|                                |       |                       |            |                               | [88]       |
| E. coli Nissle 1917            | PO    | 7/wk, x4 wks          | 10⁷ or 10⁸ CFU | clinic sensitization      | \          |
|                                |       |                       |            |                               | [94]       |
| L. rhamnosus CGMCC1.3724       | PO    | 7/wk, x12 wks (P) or 7/wk, x7 wks (M) | 5.10⁹ CFU/mL | clinic sensitization       | \ P, M    |
|                                |       |                       |            |                               | \ P, M     |
|                                |       |                       |            |                               | [42]       |
| L. crispatus KT-11 (A)         | PO    | 7/wk, x15 wks         | 1mg        | clinic sensitization          | \ A, B, C  |
| L. crispatus KT-23 (B)         | PO    | 7/wk, x15 wks         | 1mg        | clinic sensitization          | \ A, B, C  |
| L. crispatus KT-25 (C)         | PO    | 7/wk, x15 wks         | 1mg        | clinic sensitization          | \ A, B, C  |
|                                |       |                       |            |                               | [121]      |
| B. subtilis KCTC1666 + L. acidophilus KCTC3155 | PO | 7/wk, x3 wks | 1 or 2% | clinic sensitization | \ 2% > 1% |
|                                |       |                       |            |                               | [89]       |
Impact of probiotic by comparison with control mice, in term of clinical score (clinic); markers of sensitization, i.e. allergen-specific and total IgE and IgG1 (sensitization); and infiltration of inflammatory cells, i.e. lymphocytes, neutrophils, eosinophils and monocytes, in lung and/or bronchoalveolar fluid (infiltration).

↗ increase in symptoms or negative effect; \ decrease in symptoms or positive effect; → no change in symptoms or no effect

Table 6. Protocols of probiotic administration in models of atopic dermatitis

| Probiotic          | Route | Window   | Dose                        | Impact                     | References |
|--------------------|-------|----------|-----------------------------|----------------------------|------------|
| LGG                | PO    | 7/wk, x10 wks | 4.10⁴ CFU/g                 | clinic infiltration        | \           |
|                    |       |          |                             | sensitization              | \          |
|                    |       |          |                             |                             | [122]      |
| L. johnsonii NCC533| IG    | 2 days   | 1.5.10¹¹ CFU/mL             | clinic sensitization        | \          |
|                    |       |          |                             |                             | [66]       |
| L. paracasei KW3110 + LGG | PO | 7/wk, x11 wks | 0,03% or 0,3%               | clinic sensitization        | \          |
|                    |       |          |                             |                             | 0,3% > 0,03% | [93]       |
| LGG Culturelle®    | IG    | 7/wk, x6 months | 20.10⁹CFU                  | -                          |            |
| LGG                | IG    | 7/wk, x6 months | 20.10⁹CFU                  | clinic sensitization        | \          |
|                    |       |          |                             |                             | [53]       |

Author details

Elodie Neau, Marie-José Butel and Anne-Judith Waligora-Dupriet*

*Address all correspondence to: anne-judith.waligora@parisdescartes.fr

EA 4065, DHU Risques et Grossesse, Faculté des Sciences Pharmaceutiques et Biologiques, Université Paris Descartes, Sorbonne Paris-Cité, France

References

[1] Foliaki S, Pearce N, Bjorksten B, Mallol J, Montefort S, von ME. Antibiotic use in infancy and symptoms of asthma, rhinoconjunctivitis, and eczema in children 6 and 7 years old: International Study of Asthma and Allergies in Childhood Phase III. J Allergy Clin Immunol 2009 Nov;124(5):982-9.

[2] Jaakkola JJ, Ahmed P, Ieromnimon A, Goepfert P, Laiou E, Quansah R, et al. Preterm delivery and asthma: a systematic review and meta-analysis. J Allergy Clin Immunol 2006 Oct;118(4):823-30.

[3] Liem JJ, Kozyrskyj AL, Huq SI, Becker AB. The risk of developing food allergy in premature or low-birth-weight children. J Allergy Clin Immunol 2007 May;119(5):1203-9.
[4] Macpherson AJ, Slack E, Geuking MB, McCoy KD. The mucosal firewalls against commensal intestinal microbes. Semin Immunopathol 2009 Jul;31(2):145-9.

[5] Slack E, Hapfelmeier S, Stecher B, Velykoredko Y, Stoe I, Lawson MA, et al. Innate and adaptive immunity cooperate flexibly to maintain host-microbiota mutualism. Science 2009 Jul 31;325(5940):617-20.

[6] Gaboriau-Routhiau V, Rakotobe S, Lecuyer E, Mulder I, Lan A, Bridonneau C, et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity 2009 Oct 16;31(4):677-89.

[7] Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009 May;9(5):313-23.

[8] Mortha A, Chudnovskiy A, Hashimoto D, Bogunovic M, Spencer SP, Belkaid Y, et al. Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis. Science 2014 Mar 28;343(6178):1249288.

[9] Noval RM, Burton OT, Wise P, Zhang YQ, Hobson SA, Garcia LM, et al. A microbiota signature associated with experimental food allergy promotes allergic sensitization and anaphylaxis. J Allergy Clin Immunol 2013 Jan;131(1):201-12.

[10] Rodriguez B, Prioult G, Hacini-Rachinel F, Moine D, Bruttin A, Ngom-Bru C, et al. Infant gut microbiota is protective against cow’s milk allergy in mice despite immature ileal T-cell response. FEMS Microbiol Ecol 2012 Jan;79(1):192-202.

[11] Rodriguez B, Prioult G, Bibiloni R, Nicolis I, Mercenier A, Butel MJ, et al. Germ-free status and altered caecal subdominant microbiota are associated with a high susceptibility to cow’s milk allergy in mice. FEMS Microbiol Ecol 2011 Apr;76(1):133-44.

[12] Sudo N, Sawamura S, Tanaka K, Aiba Y, Kubo C, Koga Y. The requirement of intestinal bacterial flora for the development of an IgE production system fully susceptible to oral tolerance induction. J Immunol 1997 Aug 15;159(4):1739-45.

[13] Waligora-Dupriet AJ, Butel MJ. Microbiota and Allergy: From Dysbiosis to Probiotics. In: Celso Pereira, editor. Allergic Diseases-Highlights in the Clinic, Mechanisms and Treatment. InTech; 2012. p. 413-34.

[14] Abrahamsson TR, Jakobsson HE, Andersson AF, Bjorksten B, Engstrand L, Jenmalm MC. Low gut microbiota diversity in early infancy precedes asthma at school age. Clin Exp Allergy 2014 Jun;44(6):842-50.

[15] Bisgaard H, Li N, Bonnelykke K, Chawes BL, Skov T, Paludan-Muller G, et al. Reduced diversity of the intestinal microbiota during infancy is associated with increased risk of allergic disease at school age. J Allergy Clin Immunol 2011 Sep;128(3):646-52.

[16] Forno E, Onderdonk AB, McCracken J, Litonjua AA, Laskey D, Delaney ML, et al. Diversity of the gut microbiota and eczema in early life. Clin Mol Allergy 2008;6:11.
Wang M, Karlsson C, Olsson C, Adlerberth I, Wold AE, Strachan DP, et al. Reduced diversity in the early fecal microbiota of infants with atopic eczema. J Allergy Clin Immunol 2008 Jan;121(1):129-34.

Ling Z, Li Z, Liu X, Cheng Y, Luo Y, Tong X, et al. Altered fecal microbiota composition associated with food allergy in infants. Appl Environ Microbiol 2014 Apr;80(8):2546-54.

Castellazzi AM, Valsecchi C, Caimmi S, Licari A, Marseglia A, Leoni MC, et al. Probiotics and food allergy. Ital J Pediatr 2013;39:47.

Kim HJ, Kim HY, Lee SY, Seo JH, Lee E, Hong SJ. Clinical efficacy and mechanism of probiotics in allergic diseases. Korean J Pediatr 2013 Sep;56(9):369-76.

Kuitunen M. Probiotics and prebiotics in preventing food allergy and eczema. Curr Opin Allergy Clin Immunol 2013 Jun;13(3):280-6.

Herz U, Renz H, Wiedermann U. Animal models of type I allergy using recombinant allergens. Methods 2004 Mar;32(3):271-80.

Shay T, Jojic V, Zuk O, Rothamel K, Puyraimond-Zemmour D, Feng T, et al. Conservation and divergence in the transcriptional programs of the human and mouse immune systems. Proc Natl Acad Sci U S A 2013 Feb 19;110(8):2946-51.

Bix M, Wang ZE, Thiel B, Schork NJ, Locksley RM. Genetic regulation of commitment to interleukin 4 production by a CD4(+) T cell-intrinsic mechanism. J Exp Med 1998 Dec 21;188(12):2289-99.

McIntire JJ, Umetsu SE, Akbari O, Potter M, Kuchroo VK, Barsh GS, et al. Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat Immunol 2001 Dec;2(12):1109-16.

Akiyama H, Teshima R, Sakushima JI, Okunuki H, Goda Y, Sawada JI, et al. Examination of oral sensitization with ovalbumin in Brown Norway rats and three strains of mice. Immunol Lett 2001 Aug 1;78(1):1-5.

Kroghsbo S, Christensen HR, Frokiaer H. Experimental parameters differentially affect the humoral response of the cholera-toxin-based murine model of food allergy. Int Arch Allergy Immunol 2003 Aug;131(4):256-63.

Thang CL, Boye JI, Zhao X. Low doses of allergen and probiotic supplementation separately or in combination alleviate allergic reactions to cow beta-lactoglobulin in mice. J Nutr 2013 Feb;143(2):136-41.

Morafo V, Srivastava K, Huang CK, Kleiner G, Lee SY, Sampson HA, et al. Genetic susceptibility to food allergy is linked to differential TH2-TH1 responses in C3H/HeJ and BALB/c mice. J Allergy Clin Immunol 2003 May;111(5):1122-8.

Barletta B, Rossi G, Schiavi E, Butteroni C, Corinti S, Boirivant M, et al. Probiotic VSL#3-induced TGF-beta ameliorates food allergy inflammation in a mouse model of...
peanut sensitization through the induction of regulatory T cells in the gut mucosa. Mol Nutr Food Res 2013 Dec;57(12):2233-44.

[31] Bickert T, Trujillo-Vargas CM, Duechs M, Wohlleben G, Polte T, Hansen G, et al. Probiotic Escherichia coli Nissle 1917 suppresses allergen-induced Th2 responses in the airways. Int Arch Allergy Immunol 2009;149(3):219-30.

[32] Lim LH, Li HY, Huang CH, Lee BW, Lee YK, Chua KY. The effects of heat-killed wild-type Lactobacillus casei Shirota on allergic immune responses in an allergy mouse model. Int Arch Allergy Immunol 2009;148(4):297-304.

[33] Kim H, Kwack K, Kim DY, Ji GE. Oral probiotic bacterial administration suppressed allergic responses in an ovalbumin-induced allergy mouse model. FEMS Immunol Med Microbiol 2005 Aug 1;45(2):259-67.

[34] Schiavi E, Barletta B, Butteroni C, Corinti S, Boirivant M, Di FG. Oral therapeutic administration of a probiotic mixture suppresses established Th2 responses and systemic anaphylaxis in a murine model of food allergy. Allergy 2011 Apr;66(4):499-508.

[35] Zhang T, Pan W, Takebe M, Schofield B, Sampson H, Li XM. Therapeutic effects of a fermented soy product on peanut hypersensitivity is associated with modulation of T-helper type 1 and T-helper type 2 responses. Clin Exp Allergy 2008 Nov;38(11):1808-18.

[36] Bashir ME, Louie S, Shi HN, Nagler-Anderson C. Toll-like receptor 4 signaling by intestinal microbes influences susceptibility to food allergy. J Immunol 2004 Jun 1;172(11):6978-87.

[37] Berin MC, Zheng Y, Domaradzki M, Li XM, Sampson HA. Role of TLR4 in allergic sensitization to food proteins in mice. Allergy 2006 Jan;61(1):64-71.

[38] Shinagawa K, Kojima M. Mouse model of airway remodeling: strain differences. Am J Respir Crit Care Med 2003 Oct 15;168(8):959-67.

[39] Van Hove CL, Maes T, Cataldo DD, Gueders MM, Pamlans E, Joos GF, et al. Comparison of acute inflammatory and chronic structural asthma-like responses between C57BL/6 and BALB/c mice. Int Arch Allergy Immunol 2009;149(3):195-207.

[40] Matsuda H, Watanabe N, Geba GP, Sperl J, Tsudzuki M, Hiroi J, et al. Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int Immunol 1997 Mar;9(3):461-6.

[41] Suto H, Matsuda H, Mitsuishi K, Hira K, Uchida T, Unno T, et al. NC/Nga mice: a mouse model for atopic dermatitis. Int Arch Allergy Immunol 1999;120 Suppl 1:70-5.

[42] Tanaka A, Jung K, Benyacoub J, Prioult G, Okamoto N, Ohmori K, et al. Oral supplementation with Lactobacillus rhamnosus CGMCC 1.3724 prevents development of atopic dermatitis in NC/NgaTnd mice possibly by modulating local production of IFN-gamma. Exp Dermatol 2009 Dec;18(12):1022-7.
[43] de Jonge JD, Ezendam J, Knippels LM, Penninks AH, Pieters R, van LH. Lactobacillus casei Shirotia does not decrease the food allergic response to peanut extract in Brown Norway rats. Toxicology 2008 Jul 30;249(2-3):140-5.

[44] Finamore A, Roselli M, Britti MS, Merendino N, Mengheri E. Lactobacillus rhamnosus GG and Bifidobacterium animalis MB5 induce intestinal but not systemic antigen-specific hyporesponsiveness in ovalbumin-immunized rats. J Nutr 2012 Feb;142(2):375-81.

[45] Huang J, Zhong Y, Cai W, Zhang H, Tang W, Chen B. The effects of probiotics supplementation timing on an ovalbumin-sensitized rat model. FEMS Immunol Med Microbiol 2010 Nov;60(2):132-41.

[46] de Jonge JD, Knippels LM, Ezendam J, Odink J, Penninks AH, van LH. The importance of dietary control in the development of a peanut allergy model in Brown Norway rats. Methods 2007 Jan;41(1):99-111.

[47] Atkinson HA, Miller K. Assessment of the brown Norway rat as a suitable model for the investigation of food allergy. Toxicology 1994 Aug 12;91(3):281-8.

[48] Knippels LM, Penninks AH, Spanhaak S, Houben GF. Oral sensitization to food proteins: a Brown Norway rat model. Clin Exp Allergy 1998 Mar;28(3):368-75.

[49] Dearman RJ, Caddick H, Stone S, Basketter DA, Kimber I. Characterization of antibody responses induced in rodents by exposure to food proteins: influence of route of exposure. Toxicology 2001 Oct 30;167(3):217-31.

[50] Dearman RJ, Kimber I. Animal models of protein allergenicity: potential benefits, pitfalls and challenges. Clin Exp Allergy 2009 Apr;39(4):458-68.

[51] Helm RM, Ermel RW, Frick OL. Nonmurine animal models of food allergy. Environ Health Perspect 2003 Feb;111(2):239-44.

[52] Marsella R, Santoro D, Ahrens K. Early exposure to probiotics in a canine model of atopic dermatitis has long-term clinical and immunological effects. Vet Immunol Immuinopathol 2012 Apr 15;146(2):185-9.

[53] Marsella R, Santoro D, Ahrens K, Thomas AL. Investigation of the effect of probiotic exposure on filaggrin expression in an experimental model of canine atopic dermatitis. Vet Dermatol 2013 Apr;24(2):260-e57.

[54] Rupa P, Schmied J, Wilkie BN. Prophylaxis of experimentally induced ovomucoid allergy in neonatal pigs using Lactococcus lactis. Vet Immunol Immunopathol 2011 Mar 15;140(1-2):23-9.

[55] Thomas DJ, Husmann RJ, Villamar M, Winship TR, Buck RH, Zuckermann FA. Lactobacillus rhamnosus HN001 attenuates allergy development in a pig model. PLoS One 2011;6(2):e16577.
[56] Lunney JK. Advances in swine biomedical model genomics. Int J Biol Sci 2007;3(3):179-84.

[57] Meijerink M, Wells JM, Taverne N, de Zeeuw Brouwer ML, Hilhorst B, Venema K, et al. Immunomodulatory effects of potential probiotics in a mouse peanut sensitization model. FEMS Immunol Med Microbiol 2012 Aug;65(3):488-96.

[58] Schabussova I, Hufnagl K, Wild C, Nutten S, Zuercher AW, Mercenier A, et al. Distinctive anti-allergy properties of two probiotic bacterial strains in a mouse model of allergic poly-sensitization. Vaccine 2011 Feb 24;29(10):1981-90.

[59] Schabussova I, Hufnagl K, Tang ML, Hoflehner E, Wagner A, Loupal G, et al. Perinatal maternal administration of Lactobacillus paracasei NCC 2461 prevents allergic inflammation in a mouse model of birch pollen allergy. PLoS One 2012;7(7):e40271.

[60] Schwarzer M, Srutkova D, Schabussova I, Hudcovic T, Akgun J, Wiedermann U, et al. Neonatal colonization of germ-free mice with Bifidobacterium longum prevents allergic sensitization to major birch pollen allergen Bet v 1. Vaccine 2013 Nov 4;31(46):5405-12.

[61] Adam E, Delbrassine L, Bouillot C, Reynders V, Mailleux AC, Muraille E, et al. Probiotic Escherichia coli Nissle 1917 activates DC and prevents house dust mite allergy through a TLR4-dependent pathway. Eur J Immunol 2010 Jul;40(7):1995-2005.

[62] Jan RL, Yeh KC, Hsieh MH, Lin YL, Kao HF, Li PH, et al. Lactobacillus gasseri suppresses Th17 pro-inflammatory response and attenuates allergen-induced airway inflammation in a mouse model of allergic asthma. Br J Nutr 2012 Jul 14;108(1):130-9.

[63] Adel-Patient K, Bernard H, Ah-Leung S, Creminon C, Wal JM. Peanut-and cow’s milk-specific IgE, Th2 cells and local anaphylactic reaction are induced in Balb/c mice orally sensitized with cholera toxin. Allergy 2005 May;60(5):658-64.

[64] Bowman CC, Selgrade MK. Differences in allergenic potential of food extracts following oral exposure in mice reflect differences in digestibility: potential approaches to safety assessment. Toxicol Sci 2008 Mar;102(1):100-9.

[65] Bonnegarde-Bernard A, Jee J, Fial MJ, Steiner H, DiBartola S, Davis IC, et al. Routes of allergic sensitization and myeloid cell IKKbeta differentially regulate antibody responses and allergic airway inflammation in male and female mice. PLoS One 2014;9(3):e92307.

[66] Inoue R, Nishio A, Fukushima Y, Ushida K. Oral treatment with probiotic Lactobacillus johnsonii NCC533 (La1) for a specific part of the weaning period prevents the development of atopic dermatitis induced after maturation in model mice, NC/Nga. Br J Dermatol 2007 Mar;156(3):499-509.

[67] Yamanaka K, Nakanishi T, Watanabe J, Kondo M, Yamagiwa A, Gabazza EC, et al. Continuous high-dose antigen exposure preferentially induces IL-10, but intermittent antigen exposure induces IL-4. Exp Dermatol 2014 Jan;23(1):63-5.
[68] Nelde A, Teufel M, Hahn C, Duschl A, Sebald W, Brocker EB, et al. The impact of the route and frequency of antigen exposure on the IgE response in allergy. Int Arch Allergy Immunol 2001 Apr;124(4):461-9.

[69] Tobita K, Yanaka H, Otani H. Anti-allergic effects of Lactobacillus crispatus KT-11 strain on ovalbumin-sensitized BALB/c mice. Anim Sci J 2010 Dec;81(6):699-705.

[70] Shimada T, Cheng L, Yamasaki A, Ide M, Motonaga C, Yasueda H, et al. Effects of lysed Enterococcus faecalis FK-23 on allergen-induced serum antibody responses and active cutaneous anaphylaxis in mice. Clin Exp Allergy 2004 Nov;34(11):1784-8.

[71] Shimada T, Kondoh M, Motonaga C, Kitamura Y, Cheng L, Shi H, et al. Enhancement of anti-allergic effects mediated by the Kampo medicine Shoseiryuto (Xiao-Qing-Long-Tang in Chinese) with lysed Enterococcus faecalis FK-23 in mice. Asian Pac J Allergy Immunol 2010 Mar;28(1):59-66.

[72] Kim H, Lee SY, Ji GE. Timing of bifidobacterium administration influences the development of allergy to ovalbumin in mice. Biotechnol Lett 2005 Sep;27(18):1361-7.

[73] Lee J, Bang J, Woo HJ. Effect of orally administered Lactobacillus brevis HY7004 in a food allergy mouse model. J Microbiol Biotechnol 2013 Nov 28;23(11):1636-40.

[74] Schouten B, van Esch BC, Hofman GA, van Doorn SA, Knol J, Nauta AJ, et al. Cow milk allergy symptoms are reduced in mice fed dietary synbiotics during oral sensitization with whey. J Nutr 2009 Jul;139(7):1398-403.

[75] Zuercher AW, Weiss M, Holvoet S, Moser M, Moussu H, van OL, et al. Lactococcus lactis NCC 2287 alleviates food allergic manifestations in sensitized mice by reducing IL-13 expression specifically in the ileum. Clin Dev Immunol 2012;2012:485750.

[76] Maciel M, Fusaro AE, Duarte AJ, Sato MN. Modulation of IgE response and cytokine production in Peyer's patches and draining lymph nodes in sensitized mice made tolerant by oral dust mite administration. J Interferon Cytokine Res 2000 Dec;20(12):1057-63.

[77] Meulenbroek LA, van Esch BC, Hofman GA, den Hartog Jager CF, Nauta AJ, Willemsen LE, et al. Oral treatment with beta-lactoglobulin peptides prevents clinical symptoms in a mouse model for cow's milk allergy. Pediatr Allergy Immunol 2013 Nov;24(7):656-64.

[78] Qu C, Srivastava K, Ko J, Zhang TF, Sampson HA, Li XM. Induction of tolerance after establishment of peanut allergy by the food allergy herbal formula-2 is associated with up-regulation of interferon-gamma. Clin Exp Allergy 2007 Jun;37(6):846-55.

[79] Turner PV, Brabb T, Pekow C, Vasbinder MA. Administration of substances to laboratory animals: routes of administration and factors to consider. J Am Assoc Lab Anim Sci 2011 Sep;50(5):600-13.

[80] Enomoto M, Noguchi S, Hattori M, Sugiyama H, Suzuki Y, Hanaoka A, et al. Oral administration of Lactobacillus plantarum NRIC0380 suppresses IgE production and
induces CD4(+)CD25(+)Foxp3(+) cells in vivo. Biosci Biotechnol Biochem 2009 Feb; 73(2):457-60.

[81] Hougee S, Vriesema AJ, Wijering SC, Knippels LM, Folkerts G, Nijkamp FP, et al. Oral treatment with probiotics reduces allergic symptoms in ovalbumin-sensitized mice: a bacterial strain comparative study. Int Arch Allergy Immunol 2010;151(2): 107-17.

[82] Li CY, Lin HC, Hsueh KC, Wu SF, Fang SH. Oral administration of Lactobacillus salivarius inhibits the allergic airway response in mice. Can J Microbiol 2010 May;56(5): 373-9.

[83] Nonaka Y, Izumo T, Izumi F, Maekawa T, Shibata H, Nakano A, et al. Antiallergic effects of Lactobacillus pentosus strain S-PT84 mediated by modulation of Th1/Th2 immunobalance and induction of IL-10 production. Int Arch Allergy Immunol 2008;145(3):249-57.

[84] Dioszeghy V, Mondoulet L, Dhelft V, Ligouis M, Puteaux E, Benhamou PH, et al. Epicutaneous immunotherapy results in rapid allergen uptake by dendritic cells through intact skin and downregulates the allergen-specific response in sensitized mice. J Immunol 2011 May 15;186(10):5629-37.

[85] Dunkin D, Berin MC, Mayer L. Allergic sensitization can be induced via multiple physiologic routes in an adjuvant-dependent manner. J Allergy Clin Immunol 2011 Dec;128(6):1251-8.

[86] Hsieh KY, Tsai CC, Wu CH, Lin RH. Epicutaneous exposure to protein antigen and food allergy. Clin Exp Allergy 2003 Aug;33(8):1067-75.

[87] Strid J, Hourihane J, Kimber I, Callard R, Strobel S. Epicutaneous exposure to peanut protein prevents oral tolerance and enhances allergic sensitization. Clin Exp Allergy 2005 Jun;35(6):757-66.

[88] Goto K, Iwasawa D, Kamimura Y, Yasuda M, Matsumura M, Shimada T. Clinical and histopathological evaluation of Dermatophagoides farinae-induced dermatitis in NC/Nga mice orally administered Bacillus subtilis. J Vet Med Sci 2011 May;73(5): 649-54.

[89] Jung BG, Cho SJ, Koh HB, Han DU, Lee BJ. Fermented Maesil (Prunus mume) with probiotics inhibits development of atopic dermatitis-like skin lesions in NC/Nga mice. Vet Dermatol 2010 Apr;21(2):184-91.

[90] Kim HJ, Kim YJ, Kang MJ, Seo JH, Kim HY, Jeong SK, et al. A novel mouse model of atopic dermatitis with epicutaneous allergen sensitization and the effect of Lactobacillus rhamnosus. Exp Dermatol 2012 Sep;21(9):672-5.

[91] Kim HJ, Kim YJ, Lee SH, Kang MJ, Yu HS, Jung YH, et al. Effects of Lactobacillus rhamnosus on asthma with an adoptive transfer of dendritic cells in mice. J Appl Microbiol 2013 Sep;115(3):872-9.
[92] Volz T, Skabytska Y, Guenova E, Chen KM, Frick JS, Kirschning CJ, et al. Nonpathogenic bacteria alleviating atopic dermatitis inflammation induce IL-10-producing dendritic cells and regulatory Tr1 cells. J Invest Dermatol 2014 Jan;134(1):96-104.

[93] Wakabayashi H, Nariai C, Takemura F, Nakao W, Fujiwara D. Dietary supplementation with lactic acid bacteria attenuates the development of atopic-dermatitis-like skin lesions in NC/Nga mice in a strain-dependent manner. Int Arch Allergy Immunol 2008;145(2):141-51.

[94] Weise C, Zhu Y, Ernst D, Kuhl AA, Worm M. Oral administration of Escherichia coli Nissle 1917 prevents allergen-induced dermatitis in mice. Exp Dermatol 2011 Oct;20(10):805-9.

[95] Won TJ, Kim B, Lim YT, Song DS, Park SY, Park ES, et al. Oral administration of Lactobacillus strains from Kimchi inhibits atopic dermatitis in NC / Nga mice. J Appl Microbiol 2011 May;110(5):1195-202.

[96] Berin MC, Shreffler WG. T(H)2 adjuvants: implications for food allergy. J Allergy Clin Immunol 2008 Jun;121(6):1311-20.

[97] Mohan T, Verma P, Rao DN. Novel adjuvants & delivery vehicles for vaccines development: a road ahead. Indian J Med Res 2013 Nov;138(5):779-95.

[98] Blazquez AB, Berin MC. Gastrointestinal dendritic cells promote Th2 skewing via OX40L. J Immunol 2008 Apr 1;180(7):4441-50.

[99] Janeway C, Travers P, Walport M, Shlomchik MJ. Immunobiology-The Immune System in Health and Disease. 6th ed. Garland Science Publishing; 2004.

[100] Lee J, Bang J, Woo HJ. Immunomodulatory and anti-allergic effects of orally administered Lactobacillus species in ovalbumin-sensitized mice. J Microbiol Biotechnol 2013 May;23(5):724-30.

[101] Mastrangeli G, Corinti S, Butteroni C, Afferni C, Bonura A, Boirivant M, et al. Effects of live and inactivated VSL#3 probiotic preparations in the modulation of in vitro and in vivo allergen-induced Th2 responses. Int Arch Allergy Immunol 2009;150(2):133-43.

[102] Shin HS, Bae MJ, Jung SY, Shon DH. Preventive effects of skullcap (Scutellaria baicalensis) extract in a mouse model of food allergy. J Ethnopharmacol 2014 May 14;153(3):667-73.

[103] Wang JH, Fan SW, Zhu WY. Development of Gut Microbiota in a Mouse Model of Ovalbumin-induced Allergic Diarrhea under Sub-barrier System. Asian-Australas J Anim Sci 2013 Apr;26(4):545-51.

[104] Zhang B, An J, Shimada T, Liu S, Maeyama K. Oral administration of Enterococcus faecalis FK-23 suppresses Th17 cell development and attenuates allergic airway responses in mice. Int J Mol Med 2012 Aug;30(2):248-54.
[105] Matsuda A, Tanaka A, Pan W, Okamoto N, Oida K, Kingyo N, et al. Supplementation of the fermented soy product ImmuBalance effectively reduces itching behavior of atopic NC/Tnd mice. J Dermatol Sci 2012 Aug;67(2):130-9.

[106] Pellaton C, Nutten S, Thierry AC, Boudousquie C, Barbier N, Blanchard C, et al. Intragastric and Intranasal Administration of Lactobacillus paracasei NCC2461 Modulates Allergic Airway Inflammation in Mice. Int J Inflam 2012;2012:686739.

[107] Farraj AK, Harkema JR, Jan TR, Kaminski NE. Immune responses in the lung and local lymph node of A/J mice to intranasal sensitization and challenge with adjuvant-free ovalbumin. Toxicol Pathol 2003 Jul;31(4):432-47.

[108] McCusker C, Chicoine M, Hamid Q, Mazer B. Site-specific sensitization in a murine model of allergic rhinitis: role of the upper airway in lower airways disease. J Allergy Clin Immunol 2002 Dec;110(6):891-8.

[109] Southam DS, Dolovich M, O'Byrne PM, Inman MD. Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia. Am J Physiol Lung Cell Mol Physiol 2002 Apr;282(4):L833-L839.

[110] Yu J, Jang SO, Kim BJ, Song YH, Kwon JW, Kang MJ, et al. The Effects of Lactobacillus rhamnosus on the Prevention of Asthma in a Murine Model. Allergy Asthma Immunol Res 2010 Jul;2(3):199-205.

[111] Forsythe P, Inman MD, Bienenstock J. Oral treatment with live Lactobacillus reuteri inhibits the allergic airway response in mice. Am J Respir Crit Care Med 2007 Mar 15;175(6):561-9.

[112] Lyons A, O'Mahony D, O'Brien F, MacSharry J, Sheil B, Ceddia M, et al. Bacterial strain-specific induction of Foxp3+ T regulatory cells is protective in murine allergy models. Clin Exp Allergy 2010 May;40(5):811-9.

[113] Foligne B, Nutten S, Grangette C, Dennin V, Goudercourt D, Poir et S, et al. Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J Gastroenterol 2007 Jan 14;13(2):236-43.

[114] Smits HH, Engering A, van der Kleij D, de Jong EC, Schipper K, van Capel TM, et al. Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol 2005 Jun;115(6):1260-7.

[115] Zhang LL, Chen X, Zheng PY, Luo Y, Lu GF, Liu ZQ, et al. Oral Bifidobacterium modulates intestinal immune inflammation in mice with food allergy. J Gastroenterol Hepatol 2010 May;25(5):928-34.

[116] Jain S, Yadav H, Sinha PR, Kapila S, Naito Y, Marotta F. Anti-allergic effects of probiotic Dahi through modulation of the gut immune system. Turk J Gastroenterol 2010 Sep;21(3):244-50.
[117] Karimi K, Inman MD, Bienenstock J, Forsythe P. Lactobacillus reuteri-induced regulatory T cells protect against an allergic airway response in mice. Am J Respir Crit Care Med 2009 Feb;179(3):186-93.

[118] Feleszko W, Jaworska J, Rha RD, Steinhausen S, Avagyan A, Jaudszus A, et al. Probiotic-induced suppression of allergic sensitization and airway inflammation is associated with an increase of T regulatory-dependent mechanisms in a murine model of asthma. Clin Exp Allergy 2007 Apr;37(4):498-505.

[119] Blumer N, Sel S, Virna S, Patrascan CC, Zimmermann S, Herz U, et al. Perinatal maternal application of Lactobacillus rhamnosus GG suppresses allergic airway inflammation in mouse offspring. Clin Exp Allergy 2007 Mar;37(3):348-57.

[120] Kim JY, Park BK, Park HJ, Park YH, Kim BO, Pyo S. Atopic dermatitis-mitigating effects of new Lactobacillus strain, Lactobacillus sakei probio 65 isolated from Kimchi. J Appl Microbiol 2013 Aug;115(2):517-26.

[121] Tobita K, Yanaka H, Otani H. Heat-treated Lactobacillus crispatus KT strains reduce allergic symptoms in mice. J Agric Food Chem 2009 Jun 24;57(12):5586-90.

[122] Sawada J, Morita H, Tanaka A, Salminen S, He F, Matsuda H. Ingestion of heat-treated Lactobacillus rhamnosus GG prevents development of atopic dermatitis in NC/Nga mice. Clin Exp Allergy 2007 Feb;37(2):296-303.
